From Aggressive Surgical Resection to Targeted Molecular Approaches

Managing patients diagnosed with odontogenic tumors requires balancing complete lesion eradication with the preservation of facial aesthetics, speech, and masticatory function. Traditionally, aggressive surgical resection was the primary defense against locally destructive lesions like solid/multicystic ameloblastomas. However, modern surgical and molecular strategies are shifting toward more conservative, organ-sparing techniques.

Key advancements shaping patient care include:

• Virtual Surgical Planning (VSP): Computer-aided planning enables surgeons to simulate osteotomies and design customized microvascular free-flap grafts prior to entering the operating room.

• Targeted Pharmacotherapy: Identifying oncogenic driver mutations has sparked interest in BRAF and MEK inhibitors as neoadjuvant therapies to shrink large tumors before surgical excision.

• Regenerative Medicine Applications: The application of bone morphogenetic proteins (BMPs) and stem cell scaffolds aids in bone regeneration following conservative enucleation or decompression procedures.

In addition, post-surgical rehabilitation using endosseous dental implants has significantly improved quality of life for patients recovering from major mandibular or maxillary resections.

For medical device providers, pharmaceutical developers, and healthcare analysts evaluating therapeutic pipelines and clinical adoption rates, access the full odontogenic tumor Market intelligence document.